Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio
Sanofi said on Wednesday it will buy U.S. biotech Dynavax Technologies for around $2.2 billion (1.9 billion euros) in an agreed deal that will add an adult hepatitis B vaccine…